Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 −106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients

References

• Kawazoe M, Kaneko K, Yamada Z, et al. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. Clin Rheumatol. 2019:1–8.
   Web of Science ®Google Scholar
• Fialho SCMS, Bergamaschi S, Neves FS, et al. Mycophenolate mofetil in primary Sjögren’s syndrome: a treatment option for agranulocytosis. Rev Bras Reumatol. 2012;52(2):297–299. doi:10.1590/S0482-50042012000200013
   Google Scholar
• Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399–405. doi:10.1136/annrheumdis-2018-214245
   PubMed Web of Science ®Google Scholar
• Fakih R, Matiello M, Chitnis T, et al. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients. J Neurol. 2018;265(11):2688–2694. doi:10.1007/s00415-018-9050-1
   Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transpl. 2003;3(5):534–542. doi:10.1034/j.1600-6143.2003.00079.x
   PubMed Web of Science ®Google Scholar
• Sherwin CMT, Sagcal‐Gironella ACP, Fukuda T, et al. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood‐onset systemic lupus erythematosus. Br J Clin Pharmacol. 2012;73(5):727–740. doi:10.1111/j.1365-2125.2011.04140.x
   PubMed Web of Science ®Google Scholar
• Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429–455. doi:10.2165/00003088-199834060-00002
   PubMed Web of Science ®Google Scholar
• Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010;62(7):2047–2054.
   PubMed Web of Science ®Google Scholar
• Riskalla M, Somers E, Fatica R, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(7):1508–1512.
   PubMed Web of Science ®Google Scholar
• Mok CC. Mycophenolate mofetil for lupus nephritis: an update. Expert Rev Clin Immunol. 2015;11(12):1353–1364. doi:10.1586/1744666X.2015.1087314
   PubMed Web of Science ®Google Scholar
• Ling J, Shi J, Jiang Q, et al. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. Eur J Clin Pharmacol. 2015;71(1):95–106. doi:10.1007/s00228-014-1771-1
   PubMed Web of Science ®Google Scholar
• Li P, Shuker N, Hesselink DA, et al. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Transplant Int. 2014;27(10):994–1004. doi:10.1111/tri.12382
   PubMed Web of Science ®Google Scholar
• Shipkova M, Wieland E, Schütz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001;33(1–2):1080–1081. doi:10.1016/S0041-1345(00)02424-6
   Web of Science ®Google Scholar
• Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos. 2006;34(9):1539–1545. doi:10.1124/dmd.106.010553
   Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Weber L, et al.; German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit. 2002;24(3):390–399. doi:10.1097/00007691-200206000-00011
   PubMed Web of Science ®Google Scholar
• Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32:775–778. doi:10.1124/dmd.32.8.775
   PubMed Web of Science ®Google Scholar
• Guo D, Pang LF, Han Y, et al. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69(4):843–849. doi:10.1007/s00228-012-1409-0
   PubMed Web of Science ®Google Scholar
• Zhang WX, Chen B, Jin Z, et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica. 2008;38(11):1422–1436. doi:10.1080/00498250802488585
   PubMed Web of Science ®Google Scholar
• Xie XC, Li J, Wang HY, et al. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol Sin. 2015;36(5):644–650. doi:10.1038/aps.2015.7
   PubMed Web of Science ®Google Scholar
• Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25(1):1–16. doi:10.1097/00007691-200302000-00001
   PubMed Web of Science ®Google Scholar
• Batko B, Krawiec P, Osieleniec J, et al. Mycophenolate mofetil in the treatment of selected connective tissue diseases. Przegl Lek. 2013;70(9):724–729.
   Google Scholar
• Ruiz J, Herrero MJ, Boso V, et al. Impact of single nucleotide polymorphisms (SNPs) on immunosuppressive therapy in lung transplantation. Int J Mol Sci. 2015;16(9):20168–20182. doi:10.3390/ijms160920168
   PubMed Web of Science ®Google Scholar
• Bouamar R, Hesselink DA, Van Schaik RH, et al. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2012;22(6):399–407. doi:10.1097/FPC.0b013e32834a8650
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Satoh S, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008;30(5):559–564. doi:10.1097/FTD.0b013e3181838063
   PubMed Web of Science ®Google Scholar
• Kagaya H, Niioka T, Saito M, et al. Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. Xenobiotica. 2017;47(10):916–922. doi:10.1080/00498254.2016.1235742
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007;63(12):1161–1169. doi:10.1007/s00228-007-0380-7
   PubMed Web of Science ®Google Scholar
• Varnell CD, Fukuda T, Kirby CL, et al. Mycophenolate mofetil‐related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs. Pediatr Transplant. 2017;21(7):e13033. doi:10.1111/petr.13033
   Web of Science ®Google Scholar
• Michelon H, König J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010;11(12):1703–1713. doi:10.2217/pgs.10.132
   PubMed Web of Science ®Google Scholar
• Jacobson PA, Schladt D, Oetting WS, et al. Genetic determinants of mycophenolate related anemia and leukopenia following transplantation. Transplantation. 2011;91(3):309–316. doi:10.1097/TP.0b013e318200e971
   PubMed Web of Science ®Google Scholar
• Woillard JB, Picard N, Thierry A, et al. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics. 2014;24(5):256. doi:10.1097/FPC.0000000000000045
   PubMed Web of Science ®Google Scholar
• Pazik J, Ołdak M, Lewandowski Z, et al. Uridine diphosphate glucuronosyltransferase 2B7 variant p. His268Tyr as a predictor of kidney allograft early acute rejection. Transplant Proc. 2013;45(4):1516–1519. Elsevier. doi:10.1016/j.transproceed.2013.01.010
   Web of Science ®Google Scholar
• Bolin JP, Gohh R, Kandaswamy R, et al. Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter? Transplant Rev. 2011;25(3):117–123. doi:10.1016/j.trre.2010.12.003
   Web of Science ®Google Scholar
• Khan N, Binder L, Pantakani DV, et al. MPA modulates tight junctions’ permeability via Midkine/PI3K pathway in Caco-2 cells: a possible mechanism of leak-flux diarrhea in organ transplanted patients. Front Physiol. 2017:438. doi:10.3389/fphys.2017.00438
   Web of Science ®Google Scholar
• Yang JW, Lee PH, Hutchinson IV, et al. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit. 2009;31(5):542–548. doi:10.1097/FTD.0b013e3181b1dd5e
   PubMed Web of Science ®Google Scholar
• Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetil–related adverse events in pediatric heart transplant patients. J Heart Lung Transplant. 2010;29(5):509–516. doi:10.1016/j.healun.2009.11.602
   PubMed Web of Science ®Google Scholar
• Ohmann EL, Burckart GJ, Chen Y, et al. Inosine 5ʹ-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients. Pediatr Transplant. 2010;14(7):891–895. doi:10.1111/j.1399-3046.2010.01367.x
   Web of Science ®Google Scholar
• Glander P, Hambach P, Braun KP, et al. Pre‐transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transpl. 2004;4(12):2045–2051. doi:10.1111/j.1600-6143.2004.00617.x
   PubMed Web of Science ®Google Scholar
• Gensburger O, Van Schaik RHN, Picard N, et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics. 2010;20(9):537. doi:10.1097/FPC.0b013e32833d8cf5
   PubMed Web of Science ®Google Scholar
• Cao W, Xiao H, Lai X, et al. Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(2):273–279. doi:10.1016/j.bbmt.2011.06.014
   Web of Science ®Google Scholar
• Kagaya H, Miura M, Saito M, et al. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Basic Clin Pharmacol Toxicol. 2010;107(2):631–636. doi:10.1111/j.1742-7843.2010.00542.x
   PubMed Web of Science ®Google Scholar
• Gensburger O, Picard N, Marquet P. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin Chem. 2009;55(5):986–993. doi:10.1373/clinchem.2008.113936
   PubMed Web of Science ®Google Scholar
• Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics. 2007;17(5):321–330. doi:10.1097/FPC.0b013e32801430f8
   PubMed Web of Science ®Google Scholar